Lv6
1690 积分 2021-03-03 加入
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial
6天前
已完结
The predictive value of serum mRNA-RGS10 for the severity and prognosis of acute pancreatitis
6天前
已完结
Non-steroidal anti-inflammatory drugs (NSAIDs): A current insight into its molecular mechanism eliciting organ toxicities
1个月前
已完结
Recompensation after transjugular intrahepatic portosystemic shunt reduces mortality risk: A long-term follow-up study
3个月前
已完结
Recompensation after TIPS reduces the incidence of hepatocellular carcinoma and increases survival in patients with cirrhosis
3个月前
已完结
Recompensation After TIPS for Patients With Advanced Cirrhosis: A New Way to Reverse the Outcomes?
3个月前
已完结
Recompensation in Cirrhosis: Biomarkers and Strategies
3个月前
已完结
Recompensation in decompensated cirrhosis
3个月前
已完结
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial
5个月前
已完结
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial
8个月前
已完结
皖公网安备34019202002308
